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Competition binding experiments performed with 125 I-sarafotoxin (SRTX)-b and SRTX-b, SRTX-c and endothelin (ET-1 
and ET-3) using homogenates of rat right and left atria, aorta, uterus, cerebellum and candate putamen indicated hetero- 
geneity of the ET/SRTX receptor. The evidence pointed to the existence of three receptor subtypes: a high-atfmity ET-1/ 
SRTX-b subtype typical of smooth muscle (E-S~ receptor), a high-affinity SRTX-c subtype typical of the cerebellum (E-S# 
receptor), and a less selective subtype typical of the caudate putamen that binds all of these peptides with high affinity 
(E-S r receptor). 
Sarafotoxin; Endothelin; Receptor subtype; (Rat, Brain, Aorta, Heart, Uterus) 
1. INTRODUCTION 
We recently characterized a high-affinity recep- 
tor for the cardiotoxic vasoconstrictor peptides, 
the sarafotoxins (SRTX), and for the vasoconstric- 
tor peptides, endothelins (ET), in the rat heart and 
brain, and demonstrated the association of this 
receptor with phosphoinositide hydrolysis [1-5]. 
The sarafotoxins (SRTX-a, SRTX-b and SRTX-c 
[6,7]) and their structurally related mammalian 
vasoconstrictor peptides the endothelins (ET-1, 
ET-2, ET-3) [8,9] (see fig.l) were found to share 
many similarities in binding to their receptor, in 
their ability to induce phosphoinositide hydrolysis, 
regional distribution ([10] and references therein) 
and vasoconstrictive activities [8,9,11]. In spite of 
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their marked similarities in structure (fig. 1) and ac- 
tivities, especially in the case of ET-1 and SRTX-b 
[11,12], some differences were noted between the 
activities and binding properties of these two pep- 
tides and those of the other peptides of the 
ET/SRTX family [2,3,10]. Most important were 
the pronounced vasodilatory activities of ET-3 [13] 
and of SRTX-c [11] as well as the significantly 
higher binding affinities of SRTX-b and of ET-1 
for their receptors in the cerebral cortex and in the 
caudate putamen than in the cerebellum or in the 
atria [2,3,10]. If such variations are due to regional 
heterogeneity of the receptors, it should be possi- 
ble to detect significant differences among dif- 
ferent tissues with respect o binding profiles of 
peptides of the ET/SRTX family. The results 
reported here strongly suggest he existence of 
ET/SRTX receptor subtypes. 
2. EXPERIMENTAL 
Abbreviations: SRTX, sarafotoxin; ET, endothelin; E-S,,, a 
high-affinity ET-I/SRTX-b subtype; E-Sz~, a high-affinity 
SRTX-c subtype; E-S r, subtype that binds all of the peptides 
under investigation with high affinity 
SRTX-a, SRTX-b, and SRTX-c were purified to homogen- 
eity from the venom of the snake Atractaspis enggadensis [6,7]. 
125I-SRTX-b (2.5 x 1017 cpm/mol) was prepared as described 
[2]. ET-I was purchased from American Peptide Company Inc. 
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Fig.l. Structure of naturally occurring sarafotoxins [6,7] and endothelins [8,9]. 
(Santa Monica, CA) and ET-3 from Peninsula Labs Europe Ltd 
(Merseyside, England). Tissue preparation and assays for 125I- 
SRTX-b binding were as described [1-3]. 
Adult male Charles River derived (CD) rats were decapitated, 
the required tissues removed, dissected and homogenized in 
25 mM Tris-HC1 buffer, pH 7.4 (0.05 g tissue/ml buffer) con- 
taining protein inhibitors (5 U/ml aprotinin, 5/~g/ml pepstatin 
A, 0.1 mM phenylmethylsulfonyl fluoride, 3 mM EDTA and 
I mM EGTA). Aliquots (50/~l) of tissue homogenates (contain- 
ing 150/~g protein) were incubated at 25°C for 60 min with 
various concentrations of IzSI-SRTX-b (direct binding) or with 
2.5 nM ~25I-SRTX-b and various concentrations of peptides 
(competition experiments) in 25 mM Tris-HCl buffer, pH 7.4 
(total volume 200/~1). Reactions were terminated by the addi- 
tion of 3 ml of ice-cold Tris-HC1 buffer and filtration under 
vacuum through GF/C filters; adsorption of 125I-SRTX-b to 
the filters under these assay conditions was negligible. The 
filters were then washed twice with 3 ml of buffer and their 
radioactivity was estimated in scintillation counter (LKB, 1209 
Rackbeta). Assays were performed in triplicate (total binding) 
together with triplicate samples containing 1 #M SRTX-a 
(nonspecific binding). 
3. RESULTS 
In line with our previous experiments [1-4] we 
observed saturable high-affinity binding of 125I- 
SRTX-b in the rat cerebellum (Ka = 4 nM), 
caudate putamen (Kd = 0.3 nM) and heart (Kd = 
4.0 nM). Interestingly, the various regions of the 
heart showed significant differences in binding 
capacity: it was higher in the right atria than in the 
left (225 +_ 35 vs 150 _+ 25 fmol/mg protein) and 
lowest in the ventricles (18.5 _+ 4.5 fmol/mg pro- 
tein). There were no such regional differences in 
the Kd values for 125I-SRTX-b (6, 4.9 and 4.7 nM 
for the right and left atria and the ventricles, 
respectively). Thus, as judged by the direct binding 
of 125I-SRTX-b, the receptors in the caudate 
putamen and the cortex [2] appeared to be distinct 
from those in the cerebellum and the atrium. 
A more sensitive way to examine the possible x- 
istence of receptor heterogeneity s by employing a 
variety of ET/SRTX analogs in competition bin- 
ding experiments o different issues. We accor- 
dingly carried out such experiments in muscle 
tissues (right and left atria, aorta and uterus), and 
in two brain regions (cerebellum and caudate 
putamen). Results of a typical experiment 
demonstrate hat the competition patterns of the 
various peptides differ markedly among the right 
atrium, the aorta, the cerebellum, and the caudate 
putamen (fig.2). In the right atria SRTX-b and 
ET-1 are the most potent inhibitors of the binding 
of 125I-SRTX-b to its receptor, ET-3 is a moderate 
inhibitor and SRTX-c is at least 20 times less po- 
tent than either SRTX-b or ET-1. The IC50 values 
(IC5o = concentration f peptide resulting in 50% 
inhibition of the binding of 2.5 nM 125I-SRTX-b) 
for the right atria were similar to those for the left 
atria and the uterus (table 1). In the aorta, as in the 
atria, ET-1 and SRTX-b were found to be potent 
inhibitors of 125I-SRTX-b binding to its receptor; 
however, ET-3 did not inhibit the binding even at 
a concentration ashigh as 2/zM, and the IC5o of 
SRTX-c was also high (1.1 FM). Thus the two lat- 
ter peptides, while capable of inhibiting 125I- 
SRTX-b binding to its receptor in the atria (IC50 
60-70 nM to 100-200 nM for ET-3 and SRTX-c, 
respectively), are almost ineffective in competing 
with ~25I-SRTX-b for binding to its receptor in the 
aorta. The two brain regions examined here ex- 
hibited profiles which differed from each other 
and from those observed in the atria or the aorta 
(fig.2, table 1). In the caudate putamen all the 
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Fig.2. Concentration dependent inhibition of 12SI-SRTX-b inding to its receptor in various tissues by ET/SRTX peptides. Binding 
assays were as described in section 2 using 2.5 nM ~2SI-SRTX-b and various concentrations of the peptides. 
Table 1 
IC5o values of ET/SRTX peptides determined by inhibition of 
125I-SRTX-b inding to its receptors in various tissues 
IC~o (nM) 
Right Left Aorta Uterus Cere- Caudate 
atria atria bellum putamen 
ET-1 11 13 10 16 42 5 
SRTX-b 7.5 7 40 6 8 2.5 
ET-3 68 75 > 2000 230 60 10 
SRTX-c 270 110 1100 700 3.5 6 
IC5o values (IC5o = concentration f peptide resulting in 50% 
inhibition of the binding of 2.5 nM ]zSI-SRTX-b) represent the 
mean values of two to three separate xperiments similar to 
those shown in fig.2 
tested peptides howed comparable potencies in in- 
hibit ing the binding of 125I-SRTX-b to its receptor 
(ICso -- 2 .5-10 nM), whereas in ' the  cerebellum 
SRTX-c was the most potent inhibitor of binding 
(ICs0 = 3.5 nM) (table 1). 
4. D ISCUSSION 
The possible existence of receptor subtypes for 
the ET and SRTX peptide families has already 
been discussed recently by us [2,3,10]. In this study 
we employed z2SI-SRTX-b as a probe for the detec- 
t ion of ET /SRTX receptor heterogeneity in 
various murine tissues. Using this l igand and five 
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different peptides of the ET/SRTX family we 
found remarkable differences between the peptides 
in their binding potencies in the different issues. 
Receptors of smooth muscle, which we term E-S, 
receptors, displayed a high affinity for ET-1 and 
SRTX-b and a low affinity for ET-3 and SRTX-c. 
A significantly higher affinity for SRTX-c and a 
lower but comparable affinity for ET-1, SRTX-b 
and ET-3 were shown by the cerebellar receptors, 
which we designate as E-Sa receptors. A third pat- 
tern of binding was observed in the caudate 
putamen where all the peptides tested (ET-1, 
SRTX-b, ET-3 and SRTX-c) bind to the receptor 
with comparable high affinities. These receptors, 
which are less selective than either of the other 
two, we termed E-S~. receptors. It seems likely that 
the variable region of the ET/SRTX peptides [10] 
(fig. 1) plays a major part in determining their pro- 
pensity to interact with a particular receptor sub- 
type. It should be noted that the approach 
employed in this study enabled us to distinguish 
between apparent receptor subtypes by virtue of 
the observed ifferences in their structure-binding 
relationships in the various tissues. Future studies 
should be aimed at determining whether the ap- 
parent receptor subtypes described here are 
associated with different second messenger 
systems. It has already been shown that one of 
them, which binds ET-1 and SRTX-b with high af- 
finity [1,2,14,15] and appears to correspond to the 
E-S,, subtype, is associated with phosphoinositide 
hydrolysis [1,3,4] and Ca 2+ mobilization [16,17]. It 
would also be of interest to identify the en- 
dogenous agonist for the E-Sa receptors, for which 
SRTX-c appears to be a selective agonist, and to 
determine whether or not there exists a selective 
natural agonist for E-St receptor. Also worth in- 
vestigating is the relative abundancy of each of the 
apparent ET/SRTX receptor subtypes in various 
brain and peripheral tissues. 
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